{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T07:09:15Z","timestamp":1788592155370,"version":"build-2803163510"},"reference-count":53,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T00:00:00Z","timestamp":1743292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Science and Technology Council","award":["NSTC 113-2314-B-040-023-"],"award-info":[{"award-number":["NSTC 113-2314-B-040-023-"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Prostate cancer (PCa), especially metastatic castration-resistant prostate cancer (mCRPC), is a significant cancer characterized by its poor prognosis and limited treatment options. Prostate-specific membrane antigen (PSMA) has emerged as a diagnostic and therapeutic target for PCa due to its restricted expression in malignant prostate tissues. In this case, several PSMA-targeting molecules were developed for radiotherapy and immunotherapy. Antibody\u2013drug conjugates (ADCs) are a novel therapeutic approach for various carcinomas that can selectively target PSMA-positive tumor cells and minimize off-target toxicity. ADCs have made great progress in the treatment of breast and bladder cancers, and some have received FDA approval for target therapy. However, studies on PSMA ADCs are limited, and most clinical trials are at stage I or II. Therefore, this study reviewed trials about PSMA-targeting ADCs for the treatment of PCa. Clinical trials have reported a favorable pharmacokinetic profile and antitumor activity. Toxicity studies have revealed manageable adverse effects, with no significant off-target toxicity in PSMA-negative tissues. This study highlights the therapeutic potential of PSMA ADCs for the treatment of mCRPC. However, it also emphasizes the necessity of further clinical investigation to optimize efficacy, safety, and patient outcomes.<\/jats:p>","DOI":"10.3390\/cells14070513","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T05:21:04Z","timestamp":1743398464000},"page":"513","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prostate-Specific Membrane Antigen-Targeted Antibody\u2013Drug Conjugates: A Promising Approach for Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0727-6603","authenticated-orcid":false,"given":"Chia-Hsien","family":"Shih","sequence":"first","affiliation":[{"name":"School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzuo-Yi","family":"Hsieh","sequence":"additional","affiliation":[{"name":"School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan"},{"name":"Department of Urology, Chung Shan Medical University Hospital, Taichung 40201, Taiwan"},{"name":"Institute of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2375-0029","authenticated-orcid":false,"given":"Wen-Wei","family":"Sung","sequence":"additional","affiliation":[{"name":"School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan"},{"name":"Department of Urology, Chung Shan Medical University Hospital, Taichung 40201, Taiwan"},{"name":"Institute of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Henr\u00edquez, I., Roach, M., Morgan, T.M., Bossi, A., G\u00f3mez, J.A., Abuchaibe, O., and Cou\u00f1ago, F. (2021). Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC). Biomedicines, 9.","DOI":"10.3390\/biomedicines9091247"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41391-018-0121-2","article-title":"Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry","volume":"22","author":"Francini","year":"2019","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_5","first-page":"S13","article-title":"Overview of prostate-specific membrane antigen","volume":"6","author":"Chang","year":"2004","journal-title":"Rev. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.humpath.2006.11.012","article-title":"Prostate-specific membrane antigen expression as a predictor of prostate cancer progression","volume":"38","author":"Perner","year":"2007","journal-title":"Hum. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40259-017-0254-1","article-title":"Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends","volume":"31","author":"Drake","year":"2017","journal-title":"BioDrugs"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Gogia, P., Ashraf, H., Bhasin, S., and Xu, Y. (2023). Antibody-Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence. Cancers, 15.","DOI":"10.3390\/cancers15153886"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1326296","DOI":"10.3389\/fphar.2024.1326296","article-title":"Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: Potential therapies for HER2-positive urothelial carcinoma","volume":"15","author":"Shih","year":"2024","journal-title":"Front. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s11523-017-0535-0","article-title":"Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments","volume":"12","author":"Nagayama","year":"2017","journal-title":"Target. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1007\/s11095-015-1657-7","article-title":"Current ADC Linker Chemistry","volume":"32","author":"Jain","year":"2015","journal-title":"Pharm. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e0160890","DOI":"10.1371\/journal.pone.0160890","article-title":"Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics","volume":"11","author":"Waight","year":"2016","journal-title":"PLoS ONE"},{"key":"ref_13","first-page":"3499","article-title":"Topoisomerase-I inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis","volume":"18","author":"Voigt","year":"1998","journal-title":"Anticancer. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/14712598.2023.2285996","article-title":"The endosomal-lysosomal system in ADC design and cancer therapy","volume":"23","author":"Leyton","year":"2023","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody-drug conjugates: Fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/pros.23642","article-title":"Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group","volume":"78","author":"Miyahira","year":"2018","journal-title":"Prostate"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/B978-0-12-396962-0.00010-0","article-title":"Practical theoretic guidance for the design of tumor-targeting agents","volume":"503","author":"Wittrup","year":"2012","journal-title":"Methods Enzymol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/1471-2407-10-255","article-title":"The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors","volume":"10","author":"Lee","year":"2010","journal-title":"BMC Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/1078-1439(95)00004-2","article-title":"Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen","volume":"1","author":"Troyer","year":"1995","journal-title":"Urol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/(SICI)1097-0045(19970101)30:1<65::AID-PROS10>3.0.CO;2-N","article-title":"Monoclonal antibody 7E11.C5 staining of viable LNCaP cells","volume":"30","author":"Barren","year":"1997","journal-title":"Prostate"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/med.21333","article-title":"Targeted prodrug approaches for hormone refractory prostate cancer","volume":"35","author":"Aloysius","year":"2015","journal-title":"Med. Res. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1200\/JCO.23.00573","article-title":"Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of (225)Ac-J591","volume":"42","author":"Tagawa","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.2967\/jnumed.110.076174","article-title":"89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo","volume":"51","author":"Holland","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/pros.23311","article-title":"Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools","volume":"77","author":"Foss","year":"2017","journal-title":"Prostate"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2967\/jnumed.118.214403","article-title":"Evaluation of (111)In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen","volume":"60","author":"Banerjee","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/pros.23765","article-title":"Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer","volume":"79","author":"Petrylak","year":"2019","journal-title":"Prostate"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/pros.23922","article-title":"PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and\/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study","volume":"80","author":"Petrylak","year":"2020","journal-title":"Prostate"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/1535-7163.MCT-23-0927","article-title":"Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody-Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer","volume":"23","author":"Skidmore","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S974","DOI":"10.1016\/j.annonc.2023.09.2752","article-title":"1804P APEX-01: First-in-human phase I\/II study of ARX517 an anti- prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"34","author":"Shen","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_30","first-page":"606","article-title":"Technology evaluation: MLN-591, Cornell University\/BZL Biologics\/ImmunoGen\/Millennium","volume":"4","author":"Doehn","year":"2002","journal-title":"Curr. Opin. Mol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"530.e515","DOI":"10.1016\/j.urolonc.2016.07.005","article-title":"Phase 1\/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer","volume":"34","author":"Milowsky","year":"2016","journal-title":"Urol. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1158\/1535-7163.MCT-17-0982","article-title":"Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer","volume":"17","author":"Cho","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1517\/14712598.2012.693473","article-title":"Antibody-drug conjugates\u2014A perfect synergy","volume":"12","author":"Adair","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1158\/1078-0432.CCR-20-4528","article-title":"Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide","volume":"27","author":"Fleming","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer","volume":"14","author":"Scher","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1535-7163.MCT-17-0697","article-title":"Intratumoral Payload Concentration Correlates with the Activity of Antibody-Drug Conjugates","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"687926","DOI":"10.3389\/fphar.2021.687926","article-title":"Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency","volume":"12","author":"Su","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.xphs.2024.04.023","article-title":"\u201cNegative\u201d Impact: The Role of Payload Charge in the Physicochemical Stability of Auristatin Antibody\u2013Drug Conjugates","volume":"113","author":"Johann","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody-drug conjugates: Recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"Logothetis","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1053\/j.semnuclmed.2023.06.007","article-title":"Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer","volume":"53","author":"Alati","year":"2023","journal-title":"Semin. Nucl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Hennrich, U., and Eder, M. (2022). [177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer. Pharmaceuticals, 15.","DOI":"10.3390\/ph15101292"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): A single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.nucmedbio.2021.04.003","article-title":"The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: A review of the lessons learnt so far","volume":"98\u201399","author":"Heynickx","year":"2021","journal-title":"Nucl. Med. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.3390\/curroncol31030106","article-title":"177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice","volume":"31","author":"Chi","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"405","DOI":"10.32604\/or.2023.028310","article-title":"Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials","volume":"31","author":"Nambiar","year":"2023","journal-title":"Oncol. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"100713","DOI":"10.1016\/j.ctarc.2023.100713","article-title":"Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer","volume":"36","author":"Salifu","year":"2023","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/SPC.0b013e32832ea6ae","article-title":"Advances in the treatment of neutropenia","volume":"3","author":"Dale","year":"2009","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1208\/s12248-014-9710-8","article-title":"Antibody drug conjugates: Design and selection of linker, payload and conjugation chemistry","volume":"17","author":"McCombs","year":"2015","journal-title":"AAPS J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.7150\/thno.44584","article-title":"Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with (68)Ga-PSMA-11-PET","volume":"10","author":"Ferraro","year":"2020","journal-title":"Theranostics"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Sommer, U., Siciliano, T., Ebersbach, C., Beier, A.K., Stope, M.B., J\u00f6hrens, K., Baretton, G.B., Borkowetz, A., Thomas, C., and Erb, H.H.H. (2022). Impact of Androgen Receptor Activity on Prostate-Specific Membrane Antigen Expression in Prostate Cancer Cells. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031046"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/7\/513\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:05:51Z","timestamp":1760029551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/7\/513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,30]]},"references-count":53,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["cells14070513"],"URL":"https:\/\/doi.org\/10.3390\/cells14070513","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,30]]}}}